Physician profile
Julia Jaster
NPI 1215761119
$4,599.97
in general payments reported to CMS, 2019-2025
18 companies · $3,993 in 2025
The $3,993 reported for 2025 was more than what 98% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $607 · 2025: $3,993.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,588 · Education: $11.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,588.10 |
| Education | $11.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $900.41 | 2024-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $638.33 | 2024-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Lundbeck LLC | $632.50 | 2024-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $494.25 | 2024-2025 | Fanapt |
| Abbvie INC. | $434.56 | 2024-2025 | |
| Collegium Pharmaceutical, INC. | $250.84 | 2025 | Jornay Pm |
| Neurocrine Biosciences, INC. | $242.98 | 2024-2025 | Ingrezza |
| Harmony Biosciences LLC | $237.71 | 2024-2025 | |
| Supernus Pharmaceuticals, INC. | $217.37 | 2025 | Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $186.73 | 2025 | Caplyta |
| Corium, LLC | $138.01 | 2024-2025 | Azstarys |
| Tris Pharma INC | $54.55 | 2025 | Dyanavel Xr |
| Teva Pharmaceuticals USA, INC. | $46.60 | 2025 | Austedo Xr |
| Neos Therapeutics, LP | $37.36 | 2025 | Adzenys Xr-Odt |
| Ironshore Pharmaceuticals INC. | $29.70 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $23.23 | 2025 | Cobenfy |
| Sage Therapeutics, LLC | $20.27 | 2025 | Zurzuvae |
| Idorsia Pharmaceuticals US INC | $14.57 | 2025 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Jaster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.